Lv1
50 积分 2023-06-12 加入
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
1天前
已完结
RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT
23天前
已完结
Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
1个月前
已关闭
Frontline treatment of follicular lymphoma: What will it take to change current practice?
1个月前
已完结
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
1个月前
已完结
Bispecific T-cell engager therapy for multiple myeloma
2个月前
已关闭
Bispecific T-cell engager therapy for multiple myeloma
2个月前
已关闭
Combination Strategies with Menin Inhibitors for Acute Leukemia
2个月前
已完结
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
3个月前
已完结
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
4个月前
已关闭
皖公网安备34019202002308
